Abstract: Objectives　To investigate the long-term efficacy and safety of baremetal stent （BMS） implantation in patients with acute coronary syndrome （ACS）．Methods　A total of 491 ACS patients who underwent BMS implantation at the Affiliated Hospital of Beihua University between 2000 and 2005，for whom complete follow-up data were available，were enrolled in this study.Percutaneous coronary intervention was performed to implant the BMS.The following primary endpoints were recorded by the hospital：coronary angiography follow-up，outpatient follow-up，or telephone follow-up.Results　The average follow-up time was （95±39） months.During the follow-up period，there were 171 cases of major cardiac adverse events （MACE）．The incidence of MACE was 34.83%，and the average annual MACE rate was 4.38%.There were 68 death cases （13.85%）；71 cases （14.46%） of target lesion revascularization；28 cases （5.70%） of target vessel revascularization；0 cases of late stent thrombosis（LST） and very late stent thrombosis（VLST）；2 cases （0.41%） of heart failure；and 2 cases （0.41%） of coronary artery bypass graft.In-stent restenosis occurred in 106 cases （21.59%）；stent segment restenosis developed in 60 cases （12.22%）；and both types of restenosis occurred in 127 cases （25.87%）．Conclusion　The incidence of MACE，LST and VLST were lower in patients with ACS who underwent BMS implantation；the treatment thus has a favorable safety profile.

Key words: Acute coronary syndrome, Bare metal stent, Follow-up studies, Treatment outcome

摘要： 目的　探讨植入金属裸支架（BMS）治疗急性冠脉综合征（ACS）患者的长期疗效和安全性。方法　选择2000—2005年北华大学附属医院住院植入BMS随访资料完整的ACS患者491例为研究对象，均行经皮冠状动脉介入治疗植入BMS。经住院冠状动脉造影随访、门诊随访或电话随访，记录主要终点事件。结果　平均随访（95±39）个月，随访期间累积171例发生主要心脏不良事件（MACE），MACE发生率为34.83%，年均MACE发生率为4.38%。死亡68例（13.85%），靶病变血管重建71例（14.46%），靶血管重建28例（5.70%），晚期支架内血栓（LST）和极晚期支架内血栓（VLST）0例，心力衰竭2例（0.41%），冠状动脉旁路移植2例（0.41%）。发生支架内再狭窄106例（21.59%），支架节段内再狭窄60例（12.22%），支架内再狭窄合并支架节段内再狭窄127例（25.87%）。结论　植入BMS治疗ACS患者，远期MACE、LST、VLST发生率较低，安全性较好。

关键词: 急性冠状动脉综合征, 金属裸支架, 随访研究, 治疗结果